Is a blood pressure rise the only deleterious off-target effect of cholesterol ester transfer protein inhibitors?
Miura
Shin-ichiro
S
Saku
Keijiro
K
D000577:Amides; D000924:Anticholesteremic Agents / Q000009:adverse effects*; D001794:Blood Pressure / Q000187:drug effects* / Q000502:physiology; D002318:Cardiovascular Diseases / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004952:Esters; D006801:Humans; D011804:Quinolines / Q000009:adverse effects*; D016032:Randomized Controlled Trials as Topic; D013438:Sulfhydryl Compounds / Q000009:adverse effects*
D000577:Amides; D000924:Anticholesteremic Agents; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D004952:Esters; D011804:Quinolines; D013438:Sulfhydryl Compounds; C411602:dalcetrapib; C483909:torcetrapib